What Ceramon Treats: Main Uses and Benefits

Ceramon is generally applied in therapeutic domains where additional symptomatic support is needed for conditions presenting with systemic or localized discomfort, particularly those affecting circulation. The medication is commonly used in addressing symptoms associated with impaired blood flow, which may include cerebral and peripheral vasculo-metabolic disorders. Its indications encompass a range of manifestations such as those related to cerebral insufficiency—including symptoms that interfere with daily functioning like impaired memory, concentration, dizziness, and disorientation—as well as conditions involving episodic or fluctuating manifestations like Raynaud's syndrome and other syndromes due to altered peripheral flow. The medication may help address the overall symptom burden and assist with improved comfort during symptomatic periods, which supports patients during episodes of heightened discomfort.

---

Quick Fact: Relief for Vascular Symptoms

Domain	Symptom/Condition Category	Patient Benefit Focus
Cognitive	Impaired memory, concentration, disorientation, dizziness	Supports functional stability and attention
Peripheral	Intermittent claudication, Raynaud's syndrome	Eases localized discomfort and pain
Neurosensory	Vertigo, Tinnitus (vascular origin)	Assists with managing balance and auditory symptoms

Regulatory References

1. SERMION® Product Details on the Thai FDA Website

Population Eligibility and Regulatory Restrictions

The eligibility for Ceramon (Nicergoline) is defined by official regulatory documents based on cardiovascular status, age, and physiological condition. The medication is formally designated for use in adult patients (18 years and older).

Absolute Contraindications (Must Not Use)

Ceramon is strictly contraindicated for individuals with specific absolute risks as defined in regulatory labeling. These exclusions include patients with a known hypersensitivity to Nicergoline, a history of recent myocardial infarction, or the presence of acute bleeding. Use is also prohibited in patients with severe hypotension (very low blood pressure) or severe bradycardia (very slow heart rate).

Restricted or Conditional Use

Eligibility is restricted for populations where safety or efficacy data is limited. Use in children and adolescents (under 18 years) is not recommended as safety and efficacy have not been established. Furthermore, the medicine is not recommended during pregnancy or lactation. Special caution is explicitly required for patients with impaired renal function or a history of hyperuricemia or gout, necessitating careful consideration by health authorities.

Interactions with other medicines and products

Ceramon (Nicergoline) has officially documented interaction patterns based on its pharmacological activity as an alpha-blocker. These patterns primarily involve pharmacodynamic effects and altered bleeding risk, as noted in national regulatory labeling. The active metabolite of Nicergoline is formed via the CYP2D6 isoenzyme; however, formal warnings regarding CYP2D6 inhibitors or inducers are not explicitly mandated across all major labels.

---

Official Interaction Statements

Interacting Substance Category	Regulatory Description of Interaction Outcome
Antihypertensive drugs	Co-administration may potentiate the effect of the antihypertensive agent.
Beta-blocking agents	Co-administration may potentiate the cardiac effect of the beta-blocking agents.
Sympathomimetic drugs (alpha and beta agonists)	Co-administration may antagonize the vasoconstrictor effect of the sympathomimetic drugs.
Antiaggregant and anticoagulant drugs	Increases the effect on hemostasis, carrying the implication of a prolonged bleeding period.
Drugs that influence uric acid metabolism	Co-administration may increase asymptomatic increase of serum uric acid levels.

---

Population-Specific and Administration Notes

Regulatory documents highlight that a significant reduction in the urinary excretion of metabolites is observed in patients with severe renal impairment, a note relevant to clearance. Furthermore, food intake is officially documented as not significantly affecting the extent and rate of absorption of nicergoline. No specific administration timing separation is mandated by regulatory labels.

Regulation of Vascular Tone and Arterial Resistance

The action of Nicergoline begins with the selective antagonism of alpha1-adrenoceptors on vascular smooth muscle. By blocking this signaling pathway, the drug prevents the binding of norepinephrine, thereby disrupting the cascade that typically leads to vessel narrowing. This mechanism causes vasodilation and physically reduces resistance to flow, resulting in increased arterial blood flow throughout the cerebral and peripheral circulations.

---

Dual Action on Microcirculation and Blood Properties

Beyond affecting vessel diameter, Nicergoline acts as an inhibitor of platelet aggregation and modulates hemorheology by increasing red blood cell flexibility. This combined anti-aggregant and hemorheological mechanism supports the translation of arterial flow into optimized microcirculation and tissue perfusion within the smallest capillaries.

---

Direct Modulation of Neuronal Metabolism

Nicergoline exerts a direct cerebroactive effect by modulating pathways that enhance the neuronal utilization of oxygen and glucose, key energy substrates. It also provides antioxidant activity and the modulation of intracellular survival pathways, which contributes to the maintenance of functional integrity and metabolic capacity of brain cells.

Ceramon (Nicergoline) is available for administration via two distinct routes: the oral tablet and the lyophilized powder for injection, supporting both outpatient and clinical settings. The parenteral route encompasses intravenous (IV), intramuscular (IM), and intra-arterial (IA) administration, which must occur under specialized supervision.

The fundamental usage pattern requires the total daily adult dose to be divided into multiple administrations. A standard starting oral regimen is 15 mg of Nicergoline daily, typically split into three doses, though other approved regimens may range up to 60 mg daily according to prescribing guidelines. Dosage modifications are a required consideration: the dose must be carefully adjusted based on the patient's age and overall clinical factors, particularly in cases where hepatic or renal function is impaired.

The injectable form requires mandatory preparation, including reconstitution of the powder. For IV administration, the product must be further diluted in an appropriate solution (such as saline) and administered as a slow infusion.

Treatment duration is structured by a clinical constraint: if a sufficient clinical response has not been documented by the conclusion of a 12-week treatment course, the use of the medicine is typically discontinued. This protocol governs the overall administration cycle.

Overview of Studies for Ceramon

The information presented here is a high-level, non-advisory summary of the research landscape for Ceramon (Nicergoline), based on official scientific sources. This overview describes what the research has explored and where evidence gaps exist, without offering personal medical advice.

---

Evidence for Cognitive and Behavioral Symptoms

Research has explored the use of Ceramon in older adults with mild to moderate cognitive impairment, often linked to chronic cerebrovascular issues. The evidence base is built primarily on Randomized Controlled Trials (RCTs) and systematic reviews. Studies explored changes in outcomes reflecting daily functioning and overall clinical impression. Findings describe patterns observed in the studies regarding measurements of symptoms like disorientation. However, many studies used older diagnostic criteria, and the long-term effects are not fully established beyond typical one-year follow-up durations.

Evidence for Circulation and Vascular Symptoms

Ceramon was evaluated in research focusing on symptoms related to impaired cerebral circulation (chronic cerebrovascular disorders) and peripheral circulation (e.g., Raynaud's syndrome). Studies monitored outcomes reflecting daily functioning and patient-reported discomfort in the limbs.

For chronic cerebrovascular disorders, independent scientific reviews have noted that the evidence available for evaluating these broad circulation problems is very limited in its certainty. For peripheral circulation issues, the data often comes from smaller-scale clinical studies, and the certainty remains low due to reliance on uncontrolled observations and mixed findings across studies.

Research Gaps and Uncertainty

The research landscape highlights several limitations. The evidence quality varies across studies, and sample sizes were modest for many specific applications, contributing to a low certainty overall for several studied conditions. The majority of published evidence is derived from studies where research examined the older adults population, meaning data for certain groups remain insufficient.

Common questions about Ceramon (FAQ)

Q: Are there certain common foods or drinks that should be avoided with Ceramon?

Official safety information cautions against alcohol use while taking Ceramon, as this combination may lead to increased dizziness. Limiting or avoiding caffeine intake may also be suggested as a helpful measure to manage potential headaches associated with the medication.

Q: How long do most people take Ceramon for?

Official constraints specify that the medicine should be discontinued if a sufficient clinical response is not documented after a 12-week course. For patients who do benefit, clinical data indicates that many remain stable or improved after continuing treatment for periods of up to 12 months.

Q: Is Ceramon a well-studied drug, or is it relatively new?

Official information indicates that the active ingredient in Ceramon, Nicergoline, is not a new compound. It has been available and in clinical use for treating various conditions for over three decades across many countries worldwide.

Q: What are the signs of a serious allergic reaction to Ceramon?

Nicergoline, as an ergot derivative, carries the class-specific potential for serious reactions, including signs of acute toxicity or severe hypersensitivity. These symptoms may involve confusion, a rapid heartbeat (tachycardia), numbness or tingling in the extremities, nausea, and vomiting. If you experience signs of a severe reaction, seek prompt medical assistance.

Q: What are the conditions listed on the official label that Ceramon is indicated for?

The official product information states that Ceramon is used for the management of acute and chronic cerebral and peripheral metabolic-vascular disorders. This commonly covers issues like Raynaud's disease and certain oto-vestibular problems of a vascular origin, such as dizziness.

Q: How quickly does Ceramon start to work after taking it?

Clinical pharmacology data indicates that after taking an oral dose, the initial effects of Ceramon can typically be observed relatively quickly. This effect usually begins within 1 to 1.5 hours after administration.

Q: How long does the effect of Ceramon usually last?

While the onset of action is established, the regulatory clinical data does not provide a definitive, precise measure for the total length of time the effect remains in the body. The exact duration of effect is officially reported as not clinically established.

Q: Can I take Ceramon if I'm taking vitamins or supplements?

Official regulatory documents caution that Ceramon may interact with other substances. Therefore, official safety information advises that patients communicate with their healthcare provider regarding the use of all vitamins, supplements, and herbal products before starting or continuing this medicine.

Q: Does Ceramon interact with pain relievers like Tylenol or Advil?

Ceramon has been shown to interact with drugs classified as antiaggregant or anticoagulant agents. This is because Ceramon can increase the effect on hemostasis (the natural process of blood clotting), carrying the implication of a potentially prolonged bleeding period.

Q: Does Ceramon affect my ability to drive or operate machinery?

Regulatory safety warnings advise that Ceramon may cause side effects such as dizziness or other central nervous system effects. Official safety information cautions against driving or operating machinery until the patient has clearly established how the medication affects them.

Q: Do I need a special blood test before starting Ceramon?

The need for blood testing depends on the duration of treatment and other health factors. For patients on long-term therapy, regular monitoring with liver function tests (LFTs) is sometimes suggested. Monitoring may also be required for those with existing kidney disease.

Q: Are there any known issues with taking Ceramon with alcohol?

Official product safety information cautions against the use of alcohol while taking Ceramon. This is a safety measure because the combination of alcohol and the medication may lead to an increased incidence or severity of dizziness.

Q: Is Ceramon a controlled substance?

Ceramon is classified by the World Health Organization as a Peripheral Vasodilator, and it is available only as a prescription-only medicine. The active ingredient, Nicergoline, is not typically listed as a federally regulated controlled substance (Schedule I-V).

Q: What is the half-life of Ceramon?

According to the clinical pharmacokinetic data, the amount of time required for the body to eliminate half of the active drug is reported. The elimination half-life for Nicergoline is officially cited to be between 13 and 20 hours.

Q: Is there a generic version of Ceramon available?

The active ingredient in Ceramon, Nicergoline, is not exclusive to the brand name Ceramon. The official status allows for the ingredient to be manufactured and sold under various different brand names, and substitute products are available in many global markets.

Q: Is Ceramon known to cause any long-term effects on the liver?

Official safety reviews report that hepatic dysfunction (liver issues) is a rare but serious adverse reaction associated with the drug. Because of this risk, regulatory authorities suggest that regular liver function tests may be recommended for individuals on long-term treatment.

Q: Can a person develop a tolerance to Ceramon over time?

The potential for tolerance, where the medicine's effect diminishes over time, is not explicitly addressed in regulatory safety reviews. However, these same reviews have confirmed that there are no reported habit-forming tendencies associated with the use of Ceramon.

Q: Is Ceramon known to interact with caffeine?

Official patient lifestyle advice sometimes suggests limiting or avoiding caffeine consumption. This is a common non-pharmacological measure recommended to help relieve or prevent the potential occurrence of headaches associated with the medication.

Storage and Disposal Requirements for Ceramon (Nicergoline)

Ceramon must be stored and disposed of according to strict official labeling to maintain its stability and ensure safety.

Storage Conditions

Requirement	Official Instruction
Temperature	Store at a temperature not above 25 C or 30 C, in alignment with local official room temperature standards.
Protection	Protect from light and moisture; keep the product in a cool and dry place.
Container	Keep the medicine in its original package and ensure the container remains tightly closed.
Safety	Must be stored out of the sight and reach of children.

Disposal

Expired or unused Ceramon must be managed as pharmaceutical waste. Official instructions mandate that the product must be disposed of in accordance with local requirements. It must not be disposed of via wastewater or household trash. Patients are typically advised to return the product to a pharmacist or a designated collection point for safe disposal.